Drug Approval | November 06, 2025
FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
